As they age, the two mice and individuals are inclined to turn into much less energetic and reduce muscle mass and strength. Scientists led by Johan Auwerx at EPFL have not long ago found that aging mice have an accumulation of ceramides in their muscles. Ceramides are generally utilised in skincare solutions and are a variety of sphingolipid, a course of unwanted fat molecules that conduct a variety of mobile features somewhat than being applied for power manufacturing.
The researchers uncovered that, in aging, there is an overload of the protein SPT and many others, all of which are necessary to convert fatty acids and
Next, the scientists wanted to see whether reducing ceramide overload could prevent age-related decline in muscle function. They treated old mice with ceramide blockers, such as myriocin and the synthetic blocker Takeda-2, and used adeno-associated viruses to block ceramide synthesis specifically in muscle. The ceramide blockers prevented loss of muscle mass during aging, made the mice stronger, and allowed them to run longer distances while improving their coordination.
To study this effect more deeply, the scientists measured every known gene product in the muscle using a technique called RNA sequencing. “It turned out that blockade of ceramide production activates muscle stem cells, making muscles build up more protein and shifting fiber type towards fast-twitch glycolytic to produce larger and stronger muscles in aged mice,” explains Dr. Martin Wohlwend, the main collaborator in the study.
Finally, the scientists looked at whether reducing ceramides in muscle could also be beneficial in humans. They examined thousands of 70-80-year-old men and women from Helsinki and discovered that 25% of them have a particular form of a gene that reduces the gene products of sphingolipid production pathways in muscle. The people who had this ceramide-reducing gene form were able to walk longer, be stronger, and were better able to stand up from a chair, indicating healthier aging, similar to mice treated with ceramide blockers.
“These findings are very important as they provide us with a strong incentive to develop inhibitors which could be tested in humans,” says Johan Auwerx. The scientists are now embarking on collaborations with the pharmaceutical industry.
Reference: “Sphingolipids accumulate in aged muscle, and their reduction counteracts sarcopenia” by Pirkka-Pekka Laurila, Martin Wohlwend, Tanes Imamura de Lima, Peiling Luan, Sébastien Herzig, Nadège Zanou, Barbara Crisol, Maroun Bou-Sleiman, Eleonora Porcu, Hector Gallart-Ayala, Michal K. Handzlik, Qi Wang, Suresh Jain, Davide D’Amico, Minna Salonen, Christian M. Metallo, Zoltan Kutalik, Thomas O. Eichmann, Nicolas Place, Julijana Ivanisevic, Jari Lahti, Johan G. Eriksson and Johan Auwerx, 16 December 2022, Nature Aging.
The study was funded by EPFL, the European Research Council, the Swiss National Science Foundation (SNSF), Fondation Suisse de Recherche sur les Maladies Musculaires (FSRMM), Fondation Marcel Levaillant, the Academy of Finland, the Finnish Diabetes Research Society, the Folkhälsan Research Foundation, the Novo Nordisk Foundation Center for Basic Metabolic Research, Finska Läkaresällskapet, the Finnish Foundation for Cardiovascular Research, the Juho Vainio Foundation, the Signe and Ane Gyllenberg Foundation, the University of Helsinki, the Sigrid Juselius Foundation, the Finnish Ministry of Education, the Ahokas Foundation, the Emil Aaltonen Foundation, the Paavo Nurmi Foundation, the Orion Foundation, and a Scottish Senior Clinical Fellowship.